Sample Case #2
Q. A sponsor submits an application for an NDA to the FDA for an indication that exists in both adults and children. Pediatric dose and safety information is part of the submission. The FDA states that the submission is sufficient to comply with the 1998 Rule. Does the sponsor also qualify for an exclusivity extension?